Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
To access the live webcast and presentation slides, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance.
Participants will also have an opportunity to submit questions via the webcast, and selected questions will be answered during the live Q&A sessions with leadership.
Participants who are unable to join the webcast from a computer or mobile device can dial either 800-456-4352 in
The transcript and webcast replay will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live webcast and will be accessible for at least 90 days.
About Pfizer Oncology
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients’ lives.
About
At
Disclosure Notice:
The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; our Environmental, Social and Governance (ESG) priorities, strategies and goals; Pfizer Oncology; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended
The forward-looking statements in the webcast speak only as of the original date of the webcast.
Category: Finance, Research
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215326427/en/
Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226
Investor Contact:
IR@Pfizer.com
+1 (212) 733-4848
Source: